{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:08:43Z","timestamp":1778105323935,"version":"3.51.4"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Coronary atherosclerotic heart disease is a serious threat to human health. The results of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study published in 2017 put an end to the perennial debate about the anti-inflammatory treatment of coronary atherosclerotic heart disease. In addition to interleukin 1\u03b2 monoclonal antibody, interleukin 6 receptor antagonists and colchicine have also shown exciting results in clinical trials within the last 3 years. However, behind these successes, questions remain that need to be addressed. In this review, we summarize the successes and existing doubts of interleukin 1\u03b2 antibodies, interleukin 6 receptor antagonists, and colchicine in the anti-inflammatory treatment of coronary atherosclerotic heart disease.<\/jats:p>","DOI":"10.3389\/fcvm.2020.631398","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T04:26:35Z","timestamp":1612153595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes"],"prefix":"10.3389","volume":"7","author":[{"given":"Jun","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease","volume":"74","author":"Arnett Donna","year":"2019","journal-title":"J Am College Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.117.031855","article-title":"Quantifying importance of major risk factors for coronary heart disease","volume":"139","author":"Pencina Michael","year":"2019","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering lDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists","year":"2012","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12872-018-0870-9","article-title":"The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography","volume":"18","author":"Kang","year":"2018","journal-title":"BMC Cardiovasc Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","article-title":"Inflammation and atherosclerosis","volume":"136","author":"Hansson","year":"2017","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","article-title":"Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions","volume":"276","author":"Raggi","year":"2018","journal-title":"Atherosclerosis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00296-011-1900-4","article-title":"Subclinical atherosclerosis in gouty arthritis patients: a comparative study","volume":"32","author":"\u00c7ukurova","year":"2012","journal-title":"Rheum Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/annrheumdis-2016-210357","article-title":"Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment","volume":"76","author":"Andr\u00e9s","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1002\/art.21288","article-title":"Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors","volume":"52","author":"Chung","year":"2005","journal-title":"Arth Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1161\/CIRCULATIONAHA.104.507996","article-title":"Accelerated atherosclerosis in autoimmune rheumatic diseases","volume":"112","author":"Shoenfeld","year":"2005","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, c-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-Reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-Sensitivity c-Reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in iMPROVE-IT","volume":"132","author":"Bohula Erin","year":"2015","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents","volume":"124","author":"Ridker Paul","year":"2019","journal-title":"Circ Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1056\/NEJM200106283442609","article-title":"Statins and the acute-Phase response","volume":"344","author":"Munford","year":"2001","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2018","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-Dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf Stefan","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"32","author":"Nidorf","year":"2020","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial\u2020","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e001108","DOI":"10.1136\/openhrt-2019-001108","article-title":"Rationale for the aSSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute sT-elevation myocardial infarction (STEMI)","volume":"6","author":"Anstensrud","year":"2019","journal-title":"Open Heart."},{"key":"B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the mRC-ILA heart study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a Randomized clinical trial","volume":"315","author":"O'Donoghue","year":"2016","journal-title":"JAMA."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the sOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-Dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong David","year":"2020","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis - an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/0002-9149(90)90079-G","article-title":"Elevation of c-reactive protein in \u201cactive\u201d coronary artery disease","volume":"65","author":"Berk","year":"1990","journal-title":"Am J Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM199408183310701","article-title":"The prognostic value of c-reactive protein and serum amyloid a protein in severe unstable angina","volume":"331","author":"Liuzzo","year":"1994","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0140-6736(96)07591-5","article-title":"Production of c-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group","volume":"349","author":"Haverkate","year":"1997","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated c-Reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1001\/jama.286.17.2107","article-title":"Relationship between interleukin 6 and mortality in patients with unstable coronary artery diseaseEffects of an early invasive or noninvasive strategy","volume":"286","author":"Lindmark","year":"2001","journal-title":"JAMA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From c-Reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1161\/01.CIR.0000148135.08582.97","article-title":"Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis","volume":"110","author":"Schieffer","year":"2004","journal-title":"Circulation."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0002-9149(02)02306-8","article-title":"Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on c-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia","volume":"89","author":"Kinlay","year":"2002","journal-title":"Am J Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00296-009-1303-y","article-title":"Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis","volume":"31","author":"Kawashiri","year":"2011","journal-title":"Rheumatol Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: mEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2013.04.031","article-title":"Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis","volume":"229","author":"Strang","year":"2013","journal-title":"Atherosclerosis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fcvm.2017.00084","article-title":"An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice","volume":"4","author":"Akita","year":"2017","journal-title":"Front Cardiovasc Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/ATVBAHA.108.173658","article-title":"Carotid atherosclerotic plaques stabilize after stroke","volume":"29","author":"Peeters","year":"2009","journal-title":"Arteriosc Throm Vasc Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1161\/01.CIR.101.12.1372","article-title":"Expression of angiotensin iI and interleukin 6 in human coronary atherosclerotic plaques","volume":"101","author":"Schieffer","year":"2000","journal-title":"Circulation."},{"key":"B50","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/cvr\/cvq078","article-title":"Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice","volume":"87","author":"Kobara","year":"2010","journal-title":"Cardiovasc Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e003014","DOI":"10.1161\/JAHA.115.003014","article-title":"Circulating levels of iL-6 receptor and gp130 and long-Term clinical outcomes in sT-Elevation myocardial infarction","volume":"5","author":"Ritschel","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00000658-199204000-00009","article-title":"Cytokine serum level during severe sepsis in human iL-6 as a marker of severity","volume":"215","author":"Damas","year":"1992","journal-title":"Ann Surg."},{"key":"B53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1172\/JCI1368","article-title":"IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses","volume":"101","author":"Xing","year":"1998","journal-title":"J Clin Invest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.7150\/ijbs.4666","article-title":"Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases","volume":"8","author":"Tanaka","year":"2012","journal-title":"Int J Biol Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Ann Rev Pharmacol Toxicol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/MOL.0b013e328359b0a6","article-title":"Effect of interleukin 1\u03b2 inhibition in cardiovascular disease","volume":"23","author":"Qamar","year":"2012","journal-title":"Curr Opin Lipidol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1\u03b2 decreases the severity of atherosclerosis in apoE-Deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscl Thromb Vasc Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","article-title":"Inhibition of interleukin-1\u03b2 and reduction in atherothrombotic cardiovascular events in the cANTOS trial","volume":"76","author":"Everett Brendan","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2019","journal-title":"Eur Heart J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","article-title":"Interleukin-1\u03b2 has atheroprotective effects in advanced atherosclerotic lesions of mice","volume":"24","author":"Gomez","year":"2018","journal-title":"Nat Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest."},{"key":"B62","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","article-title":"Colchicine: its mechanism of action and efficacy in crystal-induced inflammation","volume":"10","author":"Nuki","year":"2008","journal-title":"Curr Rheumatol Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"684","DOI":"10.2174\/1381612824999180115103951","article-title":"Colchicine in gout: an update","volume":"24","author":"Tristan","year":"2018","journal-title":"Curr Pharm Design."},{"key":"B64","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/rheumatology\/kex353","article-title":"Use of colchicine in pregnancy: a systematic review and meta-analysis","volume":"57","author":"Indraratna","year":"2017","journal-title":"Rheumatology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheum"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12872-015-0068-3","article-title":"Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Verma","year":"2015","journal-title":"BMC Cardiovasc Disord."},{"key":"B70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjcard.2020.10.043","article-title":"Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease","volume":"140","author":"Xia","year":"2020","journal-title":"Am J Cardiol."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.11.010","article-title":"Drug repurposing? Cardiovascular effect of colchicine on patients with coronary artery disease: A systematic review and meta-analysis","author":"Tien","year":"2020","journal-title":"J Cardiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/ene.14198","article-title":"Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis","volume":"27","author":"Katsanos","year":"2020","journal-title":"Eur J Neurol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/hj.1999.v137.92052","article-title":"C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes","volume":"137","author":"Abdelmouttaleb","year":"1999","journal-title":"Am Heart J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"B8","DOI":"10.1016\/S1520-765X(02)90009-X","article-title":"Inflammation in acute coronary syndromes","volume":"4","author":"Maseri","year":"2002","journal-title":"Eur Heart J Suppl."},{"key":"B75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Mart\u00ednez","year":"2018","journal-title":"Atherosclerosis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat Rev Cardiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10557-018-6785-y","article-title":"Old drugs for new indications in cardiovascular medicine","volume":"32","author":"Arbel","year":"2018","journal-title":"Cardiovasc Drugs Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1136\/heartjnl-2020-317108","article-title":"Colchicine for acute and chronic coronary syndromes","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart."},{"key":"B80","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The nLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature."},{"key":"B82","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"14384","DOI":"10.1073\/pnas.1613156113","article-title":"Familial mediterranean fever mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation","volume":"113","author":"Van Gorp","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2014.09.148","article-title":"Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression","volume":"177","author":"Jong","year":"2014","journal-title":"Int J Cardiol."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-10049-w","article-title":"Immunomodulation of the nLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction","author":"Silvis","year":"2020","journal-title":"J Cardiovasc Transl Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of nLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-511X-13-67","article-title":"Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia","volume":"13","author":"Huang","year":"2014","journal-title":"Lipids Health Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2011.38","article-title":"Innate immune signaling in cardiac ischemia","volume":"8","author":"Arslan","year":"2011","journal-title":"Nat Rev Cardiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/cvr\/cvs018","article-title":"The innate immune response in reperfused myocardium","volume":"94","author":"Timmers","year":"2012","journal-title":"Cardiovasc Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11886-020-01358-2","article-title":"Targeting inflammation after myocardial infarction","volume":"22","author":"Mahtta","year":"2020","journal-title":"Curr Cardiol Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/eurheartj\/ehw247","article-title":"The selective nLRP3-inflammasome inhibitor mCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2017","journal-title":"Eur Heart J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e013774","DOI":"10.1136\/bmjopen-2016-013774","article-title":"Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the aLL-HEART study","volume":"6","year":"2016","journal-title":"BMJ Open."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the iL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e003031","DOI":"10.1161\/JAHA.115.003031","article-title":"NLRP3 inflammasome expression and activation in human atherosclerosis","volume":"5","author":"Paramel Varghese","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B97","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/CIRCULATIONAHA.113.002714","article-title":"Sterol regulatory element binding protein 2 activation of nLRP3 inflammasome in endothelium mediates hemodynamic-Induced atherosclerosis susceptibility","volume":"128","author":"Xiao","year":"2013","journal-title":"Circulation."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.631398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T04:26:38Z","timestamp":1612153598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.631398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":97,"alternative-id":["10.3389\/fcvm.2020.631398"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2020.631398","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"631398"}}